Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099109 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 209
- Enrollment target
NCT03099109: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT03099109 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 209 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (248% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03099109, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 209 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participants with advanced relapsed/refractory solid tumors.
Primary Outcome
Dose Limiting Toxicity (DLT) is defined as an adverse event (AE) that meets protocol defined DLT criteria during cycle 1 and is at least possibly related to study drug.
Interventions
- DRUG LY3300054
- DRUG LY3321367
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 1 |
What the finished NCT03099109 record still lists
NCT03099109 is an interventional study that assigns participants to a tested intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (248% higher).
The record links to 0 conditions, and to 2 interventions - of which LY3300054 is the first listed.
NCT03099109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03099109 about?
NCT03099109 is a clinical study titled "A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors". The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participa...
What is the current status of trial NCT03099109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 209 participants. The study started on 2017-04-12. Estimated completion is 2023-08-30.
What interventions are being tested in trial NCT03099109?
The interventions under investigation include: LY3300054 (DRUG), LY3321367 (DRUG).
Who is sponsoring clinical trial NCT03099109?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03099109's enrollment target sits among peer trials
209 250th of 2000 higher than 1,751 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04742634 · 209 participants · Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- NCT07214688 · 209 participants · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI